Aptevo Therapeutics (APVO) Net Income towards Common Stockholders (2015 - 2026)
Aptevo Therapeutics (APVO) posted Net Income towards Common Stockholders of -$6.8 million for Q1 2026, down 9.51% sequentially from -$6.2 million in Q4 2025, and down 6.02% YoY from -$7.2 million in Q1 2025.
Aptevo Therapeutics (APVO) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Net Income towards Common Stockholders for 12 years, with the latest figure at -$6.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 6.02% year-over-year to -$6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.9 million (down 62.39% YoY) and the FY2025 annual result came in at -$27.5 million, down 14.12% from the prior year.
- Net Income towards Common Stockholders declined to -$6.8 million in Q1 2026 per APVO's latest filing, from -$6.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $946000.0 in Q1 2023 and troughed at -$9.0 million in Q3 2025.
- A 5-year average of -$3.4 million and a median of -$5.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders surged 431.46% in 2023, then tumbled 2254.27% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at $521000.0 in 2022, then slumped by 43.76% to $293000.0 in 2023, then sank by 2254.27% to -$6.3 million in 2024, then climbed by 1.71% to -$6.2 million in 2025, then slipped by 9.51% to -$6.8 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$6.8 million, -$6.2 million, and -$9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | -6.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.36 Mn |
| Mar 31, 2026 | -6.79 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Sep 30, 2025 | -9.03 Mn |
| Jun 30, 2025 | -6.91 Mn |
| Mar 31, 2025 | -6.41 Mn |
| Dec 31, 2024 | -6.31 Mn |
| Sep 30, 2024 | -5.10 Mn |
| Dec 31, 2023 | 293,000.00 |
| Mar 31, 2023 | 946,000.00 |
| Dec 31, 2022 | 521,000.00 |
| Sep 30, 2022 | 165,000.00 |
| Jun 30, 2022 | 149,000.00 |
| Mar 31, 2022 | 178,000.00 |
| Dec 31, 2021 | 325,000.00 |
| Sep 30, 2021 | 80,000.00 |
| Jun 30, 2021 | 132,000.00 |
| Mar 31, 2021 | 414,000.00 |
| Dec 31, 2020 | -14.64 Mn |
| Sep 30, 2020 | 157,000.00 |